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ABSTRACT OF DISSERTATION

EVALUATING THE IMPACTS OF ANTIDEPRESSANT USE ON THE RISK OF
DEMENTIA
Dementia is a clinical syndrome caused by neurodegeneration or cerebrovascular
injury . Patients with dementia suffer from deterioration in memory, thinking, behavior
and the ability to perform everyday activities2. Since there are no cures or diseasemodifying therapies for dementia3,4, there is much interest in identifying modifiable risk
factors that may help prevent or slow the progression of cognitive decline4,5. Medications
are a common focus of this type of research.6,7
Importantly, according to a report from the Centers for Disease Control and
Prevention (CDC), 19.1% of the population aged 60 and over report taking
antidepressants during 2011-2014, and this number tends to increase8. However,
antidepressant use among the elderly may be concerning because of the potentially
harmful effects on cognition9-12. To assess the impacts of antidepressants on the risk of
dementia, we conducted three consecutive projects.
In the first project, a retrospective cohort study using Marginal Structural Cox
Proportional Hazards regression model with Inverse Probability Weighting (IPW) was
conducted to evaluate the average causal effects of different classes of antidepressant on
the risk of dementia. Potential causal effects of selective serotonin reuptake inhibitors
(SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants (AAs) and tri-cyclic antidepressants (TCAs) on the risk of dementia were
observed at the 0.05 significance level. Multiple sensitivity analyses supported these
findings.
Unmeasured confounding is a threat to the validity of causal inference methods.
In evaluating the effects of antidepressants, it is important to consider how common
comorbidities of depression, such as sleep disorders, may affect both the exposure to antidepressants and the onset of cognitive impairment. In this dissertation, sleep apnea and
rapid-eye-movement behavior disorder (RBD) were unmeasured and thus uncontrolled
confounders for the association between antidepressant use and the risk of dementia. In
the second project, a bias factor formula for two binary unmeasured confounders was
derived in order to account for these variables. Monte Carlo analysis was implemented to
estimate the distribution of the bias factor for each class of antidepressant. The effects of
antidepressants on the risk of dementia adjusted for both measured and unmeasured
1

confounders were estimated. Sleep apnea and RBD attenuated the effect estimates for
SSRI, SNRI and AA on the risk of dementia.
In the third project, to account for potential time-varying confounding and
observed time-varying treatment, a multi-state Markov chain with three transient states
(normal cognition, mild cognitive impairment (MCI), and impaired but not MCI) and two
absorbing states (dementia and death) was performed to estimate the probabilities of
moving between finite and mutually exclusive cognitive state. This analysis also allowed
participants to recover from mild impairments (i.e., mild cognitive impairment, impaired
but not MCI) to normal cognition, and accounted for the competing risk of death prior to
dementia. These findings supported the results of the main analysis in the first project.
KEYWORDS: dementia, antidepressants, inverse probability weighting, unmeasured
confounding, multi-state Markov chain
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CHAPTER ONE. INTRODUCTION
1.1. Dementia
Dementia, which includes Alzheimer’s disease, vascular dementia, Lewy body
disease and frontotemporal dementia, is a clinical syndrome caused by neurodegeneration
or cerebrovascular injury1. Patients with dementia suffer from deterioration in memory,
thinking, behavior and the ability to perform everyday activities2.
In recent years, dementia has become an important public health topic worldwide
due to its increasing prevalence in an aging society2. In the United States, the population
age 65 and older is estimated to be 53 million in 201813, and this number is still
increasing14. The number of Americans age 65 and older with Alzheimer’s or a related
dementia in 2018 is estimated to be 5.5 million13. In other words, one in ten Americans
age 65 and older has dementia.
Dementia is known to be associated with extremely heavy burden on families and
communities. It has been estimated that the yearly monetary cost per person attributable
to dementia was between $41,689 and $56,290, depending on the method used to value
informal care15. Therefore, the total monetary cost of dementia in 2010 has been
estimated to be between $157 billion and $215 billion15.
As there are no cures or disease-modifying therapies available for any disease that
causes dementia3,4, there is major interest in identifying modifiable risk factors for
dementia4,5, such as life style factors, medication use6,7, and comorbid health conditions16.
In this dissertation, we will be focusing on antidepressant use.
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1.2. Antidepressants
Antidepressants are widely used among the elderly. According to a report from the
Centers for Disease Control and Prevention (CDC), 19.1% of the population aged 60 and
over reported taking antidepressants during 2011-2014, and this number tends to
increase8. Besides treating depression, antidepressants have been used for treating other
psychiatric disorders, such as anxiety, serious phobias, and post-trauma stress disorder1720

. In some cases antidepressants can be used for treating long-term pain21. which is a

common health condition among the elderly.
However, antidepressant use among the elderly may be concerning because of the
impacts of the underlying age-related pharmacokinetic and pharmacodynamic safety
issues and potentially harmful drug-drug interactions on cognition22,23. For example,
evidence has suggested that tri-cyclic antidepressants (TCAs) may increase the risk of
cardiac arrhythmia and should be avoided for the elderly who are at high risk of
cardiovascular diseases22,24, which is a risk factor for dementia. Another study suggests
that combined use of antidepressants and NSAIDs is associated with an increased risk of
intracranial hemorrhage within 30 days of initial combination25. More importantly, the
conclusions regarding the effects of antidepressants on the risk of dementia are
inconsistent26-28. Thus, the use of antidepressants among the geriatric population is a
critical but under-investigated public health topic.

1.3. Causal Inference for Observational Studies in Pharmacoepidemiology
Ideally, the causal effects of treatments on outcomes should be investigated in a
randomized study so that trial arms are exchangeable groups and the differences in
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outcomes reflect the effects of the treatment rather than differences in participant
characteristics29. However, randomized studies are not always feasible in real life, since
some treatments cannot be randomized due to ethical considerations, and sometimes it is
difficult to conduct head-to-head trials. If the subjects select their own treatments or the
treatments are assigned to them by clinical professionals, the differences in outcomes
may due to selection bias and confounding rather than the effects of the treatments29.
For observational studies in pharmacoepidemiology, people may be interested in
the average causal effects of a certain medication on a well-defined population. Hernán
and Robins defined that an average causal effect of treatment A on outcome Y is present
if 𝐸𝐸[𝑌𝑌 𝑎𝑎=1 ] ≠ 𝐸𝐸[𝑌𝑌 𝑎𝑎=0 ], where 𝑌𝑌 𝑎𝑎 is the counterfactual outcome under a given treatment

regimen A=a30. In other words, there is a causal effect of the treatment when the same
population is observed under treatment and no treatment, and experiences a different
outcome under each. In randomized trials, the treatment arms are assumed to be
exchangeable (i.e., it doesn’t matter which group receives which treatment; the effects of
the treatment should be the same in any group randomly assigned to that treatment), and
thus causal effects are identifiable. Causal inference methods facilitate using
observational data to determine the average causal effect by simulating randomized
treatment assignment.
Analytically the population average causal effects of a treatment can be estimated
by Marginal Structural Models with Inverse Probability Weighting (IPW) estimator,
given that the assumptions of conditional exchangeability, positivity, consistency, and
correct model specification are satisfied30. IPW creates a pseudo-population in which the
initiation of the treatment is not related to the measured confounders; to interpret the IPW
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estimates as causal effects, we must assume there is no unmeasured confounding30. In
such a pseudo-population, the average causal effects of the treatments on the outcomes
can be estimated by regressing the outcome on the treatment using a marginal structural
model, which is a conventional regression model weighted by IPW31.
The traditional approach to adjust for confounding is to include confounders as
covariates in a multiple regression model32. However, recent advances in epidemiological
methods have shown that the traditional approach is often inadequate32,33. Greenland et al.
suggested that the major drawback of the traditional approach to adjusting for
confounders using statistical models is that they need many parametric assumptions that
are not known to be correct or may be incorrect33. Therefore, in a high-dimensional study
with many covariates and multi-group treatment, causal diagrams, such as Directed
Acyclic Graphs (DAGs), can be used to identify a minimal sufficient set of adjustment
variables that confound the effects of treatments on the outcomes by depicting a set of
hypotheses about the causal process29.
One of the key assumptions for causal inference in epidemiology is that there
should not be any unmeasured confounding. Nevertheless, this assumption is often
violated in observational studies. When unmeasured confounding exists but fails to be
controlled for, the estimated treatment effects may be biased34. Monte Carlo Sensitivity
Analysis could be used to adjust the data by estimating the sensitivity parameters for the
omitted sources of uncontrolled confounding35.
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1.4. About this Research
The goal of this research is to investigate the causal effects of different classes of
antidepressant medications on the risk of dementia using causal inference strategies. Data
were obtained from the National Alzheimer’s Coordinating Center (NACC) Uniform
Data Set (UDS). We hypothesize that antidepressant use among the elderly may increase
the risk of dementia, and the impacts may be heterogeneous for different classes of
antidepressant.
In Chapter Two, a new user design retrospective cohort study was conducted to
evaluate the causal effects of different classes of antidepressant on the risk of dementia
by performing a Marginal Structural Cox Proportional Hazard Regression Model with an
Inverse Probability Weighting estimator. Sensitivity analyses were conducted to assess
the robustness of the main analysis results.
In Chapter Three, the impacts of unmeasured confounders were assessed.
Unmeasured confounding is a threat to the validity of causal inference methods. In
evaluating the effects of anti-depressants, it is important to consider how common
comorbidities of depression, such as sleep disorders, may affect both the exposure to antidepressants and the onset of cognitive impairment. In this dissertation, sleep apnea and
rapid-eye-movement behavior disorder (RBD) were identified as confounders by our
hypothesized causal model but were unmeasured and thus uncontrolled confounders for
the association between antidepressant use and the risk of dementia. A bias factor
formula for two binary unmeasured confounders was derived in order to account for these
variables. Monte Carlo analysis was implemented to estimate the distribution of the bias
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factor for each class of antidepressant. The effects of antidepressants on the risk of
dementia adjusted for both measured and unmeasured confounders were estimated.
In Chapter Four, a multi-state Markov chain with three transient states (normal
cognition, impaired but not MCI, and MCI) and two absorbing states (dementia and death
prior to dementia) was built to account for changes in treatment over time and timevarying covariates. A series of multinomial logistic regression models were constructed
to model the log-odds of transitions between any two transient states and transitions
between a transient state and an absorbing state. The long-run behavior of the chain was
also evaluated.
Finally, a conclusion of this research and discussion of directions for future
studies can be found in Chapter Five.
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CHAPTER TWO. THE EFFECTS OF ANTIDEPRESSANT USE ON THE RISK OF
DEMENTIA: A RETROSPECTIVE COHORT STUDY
2.1. Introduction
Dementia has become a significant public health issue worldwide in recent years2.
Patients with dementia suffer from deterioration in memory, thinking, behavior and the
ability to perform everyday activities1. The prevalence of age-related dementia in the
United States in 2010 is estimated to be 14.7% for those aged 70 or older36. Since there
are no cures or disease-modifying therapies for dementia3,4, there is much interest in
identifying modifiable risk factors that may help prevent or slow the progression of
cognitive decline4,5. Medications are a common focus of this type of research6,7, and
antidepressant use is a possible modifiable risk factor in the geriatric population.
Importantly, according to a report from the Centers for Disease Control and Prevention
(CDC), 19.1% of the population aged 60 and over report taking antidepressants during
2011-20148. In other words, one fifths of this population were using antidepressants.
Antidepressants can be identified based on their mechanisms of action: selective
serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors
(SNRIs), tri-cyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and
atypical antidepressants (AAs). All these antidepressants work to increase the levels of
one or more of the neurotransmitters in the patient’s body—serotonin, norepinephrine, or
dopamine—but different classes of drugs achieve this goal very differently37.
SSRIs help to reduce symptoms of depression through increasing the amount of
serotonin by blocking the re-absorption of serotonin in the brain38. SNRIs differ from
SSRIs in that SNRIs increase the levels of two neurotransmitters: serotonin and
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norepinephrine39. TCAs were one of the earliest antidepressants developed, and they will
also increase the levels of serotonin and norepinephrine40. However, TCAs lead to more
side effects compared to SSRIs and SNRIs, because TCAs will simultaneously impact
other chemicals in the human brain41. MAOIs function by preventing monoamine oxidase,
an enzyme, from removing serotonin, norepinephrine, and dopamine so that the levels of
these neurotransmitters are maintained in brain42. MAOI users also report more side
effects compared to SSRI or SNRI users due to MAOI’s impact on other
neurotransmitters and the digestive system43. AAs work through novel mechanisms of
action, but in general they also elevate the levels of serotonin, norepinephrine, or
dopamine44,45.
According to guidelines of the National Health Services (NHS) in England46,
when antidepressant therapy is necessary, SSRIs are normally considered as the first-line
treatment; other classes of antidepressants are generally used as second-line or third-line
treatment. A combination of two different classes should be initiated by specialists only.
However, it should be noted that the selection of a particular medication for a particular
patient depends on a variety of factors, such as the avoidance of specific side effects and
the presence of comorbidities, so there is not one antidepressant medication that is clearly
more effective than another at the population level47.
No strong conclusions can be made from current studies focusing on the
relationship between antidepressant use and dementia. First, different antidepressants
work via different mechanisms of action, and there are very few studies comparing the
potential heterogeneous effects of antidepressant classes on the risk of dementia among
the elderly48,49. Second, the geriatric population is usually under-represented in clinical
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trials, thus the effects of antidepressants on the elderly in settings where causal inference
is straightforward remain under-investigated50. Finally, existing studies investigating the
effects of antidepressants made inconsistent conclusions. Some in vivo studies showed
that chronic SSRI treatment reduces amyloid-β accumulation, which is a marker for
Alzheimer’s disease, in mice, and this benefit also appears to be true in humans26-28.
However, a randomized, placebo-controlled, double-blind, parallel group clinical trial
study showed that fluoxetine, a commonly used SSRI, is associated with worsening
cognitive functions51. A cross-over clinical study focusing on the effect of SNRI on
memory and mental processing speed concluded that SNRIs may improve memory,
mental processing speed and motor performance52, but a large cohort study suggests that
SNRI use is associated with increased risk for dementia51. Some AAs, such as
amitriptyline, dothiepin, mianserin, and trazodone, may impair attention and ability to
concentrate53. Yet, another study recommends that AAs are preferable in the elderly
patients because use of risperidone, a type of AA, in Alzheimer’s disease subjects did not
result in a significant reduction in MMSE score over a 12-week period compared with
placebo group, while a lower rate of adverse events was observed54. With inconsistent
information, it is difficult to draw any conclusions regarding the impacts of
antidepressants on the risk of dementia.
To summarize previous studies on human subjects investigating the relationship
between antidepressant use and dementia, both randomized trials and observational
studies have limitations. Most studies investigating this topic are preclinical studies with
animal subjects. In randomized clinical trials, the elderly were usually excluded from the
eligible patient cohort, so the findings may not be generalizable to the geriatric
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population. On the other hand, the existing observational studies suffer from
methodologic flaws such as confounding by indication and unmeasured confounders.
Additionally, none of the previous studies investigated the causal effects.
Hence, the goal of this study was to evaluate the causal effects of different classes
of antidepressant medications on the risk of dementia by conducting a retrospective
cohort study using the National Alzheimer’s Coordinating Center’s (NACC) Uniform
Data Set (UDS). This study primarily focused on SSRIs, SNRIs, AAs and TCAs. MAOIs
were not included due to small numbers who reported taking these drugs.

2.2. Methods
2.2.1. Data Source and Study Population
This study used the NACC’s Uniform Data Set (UDS), which is a prospective and
longitudinal clinical evaluation database48. The data are collected annually from
Alzheimer’s Disease Centers (ADCs) funded by the National Institute on Aging (NIA)55.
Since September 2005, all participants in ADC studies have been followed by a standard
data collection protocol (i.e., the UDS). The UDS was collected by trained clinicians and
clinical practitioners from participants and their co-participants during in-person office
visits, home visits and telephone calls. Although the focus of the ADCs is Alzheimer’s
disease, the UDS also enrolls subjects with a wide range of other related disorders, such
as vascular dementia, Lewy body dementia and frontotemporal lobar degeneration.
Participants with normal cognition and milder cognitive impairments, like MCI, are also
included.
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Generally speaking, the UDS subjects are referral-based or volunteer case series56,
thus they are unlikely to be a representative sample of the U.S. population. As of
September 2018, among all 38,836 UDS subjects, 35.1% carried a diagnosis of normal
cognition, 17.2% were MCI, 4.3% were impaired but not MCI, and 43.4% were
diagnosed with any form of dementia. As a comparison, only 8.8% of the U.S. population
aged 65 and above was diagnosed with dementia in 201257. In addition, the UDS
population consists of slightly higher percentage of females (57.1%), which is consistent
with the general population of older adults (56.9%)58. However, the percentage of
subjects with higher education (72.3% had some college or more) is much higher than the
general population of older adults (49.7% of 65 and older had some college or more)59.

2.2.2. Study Design
A new-user design retrospective cohort study matched on the index visit was
conducted using the NACC UDS from September 2005 to September 2018 (see Figure
2.1). Besides the exclusion criteria applied by each ADC, this study further excluded
subjects who were:
1) prevalent dementia patients at the index visit;
2) prevalent antidepressant users defined based on reported use at the initial UDS
visit;
3) MAOI users or combination users;
4) younger than 65-years-old at the at the initial UDS visit;
5) missing data on any of the covariates in the propensity score model.
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In this study, the index visit is defined as the UDS visit when a subject first
reported initiation of an antidepressant. The baseline visit is defined as the UDS visit
prior to the index visit. The initial visit is the first UDS visit. Due to the sparseness of
MAOI users, subjects who reported using this type of antidepressants were excluded
from the study. Participants who reported using more than one type of antidepressant
were also excluded due to their heterogeneity. Hence, we make comparison among nonusers, SSRI users, SNRI users, TCA users and AA users.

2.2.3. Treatment and comparison groups
Among the eligible subjects, those who ever initiated one or more of the
treatments prior to a relevant event (dementia, death prior to dementia, or the last UDS
visit) were identified. Each subject in the treatment groups was randomly matched with
three nonusers who had not started any antidepressant at that same UDS visit to avoid the
immortal time bias60. Matched non-users may report antidepressant use at a later UDS
visit, but they will not contribute follow-up time to the treated cohort. This is similar to
an intent-to-treat design.
For example, participant A initiates a certain antidepressant medication at the
second UDS visit (Figure 2.2). Three participants (C, G and I) who have not initiated any
antidepressant at their second UDS visit will be randomly selected as control subjects.
The second UDS visit is the index visit for all four participants. The visit prior to the
index-visit, which is first visit in this example, is the baseline visit for these four subjects.
Although participant C starts treatment at the fifth visit, this patient will stay in the
control group.
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2.2.4. Antidepressant Measurement
At each UDS visit, subjects were asked about their antidepressant use within the
past two weeks before the current visit. Four classes of antidepressants, SSRIs, SNRIs,
TCAs, and AAs were identified based on subjects’ self-reported medication use at the
index visit. For the purpose of this study, prevalent antidepressant users were removed,
and incident antidepressant users and non-users were included.
Prevalent users were defined as active users of any type of antidepressant
identified in this study at the initial UDS visit. Incident antidepressant users were defined
as new users of any type of antidepressant identified in this study during the follow-up.
Non-users were defined as participants who never initiated any antidepressant identified
in this study during the follow-up. If a participant reported using two or more classes of
antidepressant at one UDS visit, this participant was defined as combination users. As
mentioned earlier, combination users were not of the primary interest in this study, five
groups are compared: SSRI group, SNRI group, AA group, TCA group and the non-users.
Table 2.1 summarizes the antidepressant classification and the generic drug names in
each class.

2.2.5. Dementia Status Assessment
Clinicians assessed the cognitive and behavioral status of participants at each
UDS visit. Cognitive status is classified into four levels in the UDS: normal cognition,
MCI, impaired but not MCI, and dementia. Dementia incidence is defined as the first
dementia diagnosis after the index visit. According to the criteria by NACC, a series of
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cognitive or behavioral symptoms should be met. Specially, to be diagnosed with
dementia, the cognitive impairment should (taken from the UDS coding guide book)61:
1) interfere with ability to function as before at work or at usual activities;
2) represent a decline from previous levels of functioning;
3) not be explained by delirium or major psychiatric disorder;
4) include cognitive impairment detected and diagnosed through a combination of
history-taking and objective cognitive assessment (bedside or neuropsychological
testing).
And, the participant must also show impairment in one or more of the following domains:
1) ability to acquire and remember new information;
2) reasoning and handling of complex tasks, poor judgment;
3) visuospatial abilities;
4) language functions;
5) changes in personality, behavior, or comportment.

2.2.6. Death Assessment
Mortality information is obtained from the NACC Milestone Form62. Year and
month of death are obtained for subjects who are known to be deceased. Day of death
was set to be 15th since this information was not available in the Milestone Form, and we
assumed deaths would be distributed randomly and uniformly during the month (thus, the
mean day of death for all participants who died in a particular month would be the middle
of the month). If a participant died before developing any form of dementia, then this
subject is coded to have experience the event of death. Deaths occurring after dementia
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diagnosis are not of interest in this study since our focus was on risk of dementia, with
death as a competing event.

2.2.7. Administrative Censoring
According to the protocol of the UDS, participants may be censored because
participants or co-participants asked to withdraw from the study, or participants could
also be withdrawn due to an ADC decision or protocol62. For the purpose of this study, if
subjects never developed dementia or died, they were right-censored at the last contact.
This includes both participants who withdrew and participants still under follow-up.

2.2.8. Baseline Covariates Assessment
A Directed Acyclic Graph (DAG) was constructed via DAGitty.net63 to identify
the minimal sufficient adjustment set based on the hypothesized causal association
between antidepressant use and dementia (Figure 2.3). Variables were included in the
DAG regardless of their availability in the NACC UDS data. Demographic variables
included age, sex, race and education. Lifestyle variables were smoking and alcohol
abuse. Comorbidities were traumatic brain injury (TBI), Parkinson’s disease,
hypertension, type 2 diabetes, high cholesterol, stroke, cardiovascular disease (CVD),
depression status, any psychiatric conditions except for depression (i.e. post-traumatic
stress disorder, bipolar disorder, schizophrenia or anxiety), standard CDR sum of boxes
and cognitive status. History of medication use variables were NSAIDs, opioid
medications, and anti-anxiety medications. Genetic information included the ApoE ε4
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allele status. Prior antidepressant use was not considered in this graph because prevalent
antidepressant users were excluded from the study.
The minimal sufficient adjustment set included the baseline values of age, pain
medication use (as proxy for chronic pain), sleep disorders, depression status, GDS score,
any other psychiatric conditions except for depression (i.e., post-traumatic stress disorder,
bipolar, schizophrenia, anxiety, obsessive-compulsive disorder or developmental
neuropsychiatric disorder), standard CDR sum of boxes and cognitive status.

2.2.9. Statistical Analysis
2.2.9.1. Descriptive analysis
Subject characteristics at baseline stratified by the treatment groups were
summarized for the original cohort and the pseudo-cohort (the pseudo-cohort is defined
and described below). Means and standard deviations were reported for normallydistributed continuous variables. Median and interquartile range were reported for nonnormally-distributed variables. Frequencies and percentages were reported for categorical
variables.

2.2.9.2. Main analysis
Kaplan-Meier curves by treatment groups were plotted to visualize the
distribution of dementia-free-survival-times across the five groups. Log-Rank tests
between each treatment group and the control group were performed to quantitively
compare the median dementia-free-times.

16

Cox Proportional Hazard Regression with IPW was performed to evaluate the
effects of different antidepressant classes on the risk of dementia. To perform this
analysis, it is necessary to 1) build propensity score models to obtain the weights for
balancing the subject baseline characteristics; 2) apply weights to the original cohort to
construct a “weighted and balanced” pseudo-cohort; 3) evaluate the balance of the
pseudo-cohort; and 4) construct a weighted Cox Proportional Hazards regression with
antidepressant treatment status as the only predictor in the model. The model in step 4 is
called a marginal structural model and estimates the marginal causal effects of
antidepressants on the risk of developing dementia. Standardized Mean Differences
(SMDs) between each treatment group and the control group were calculated to assess
the effectiveness of the inverse probability weighting in balancing the baseline
characteristics of the treated and untreated groups in the pseudo-cohort.
Two propensity score models were built to obtain two sets of weights respectively:
weights for balancing the prognostic factors of receiving different classes of
antidepressant (i.e. inverse probability of treatment weights), and the weights for
accounting for censoring (i.e. inverse probability of censoring weights).
The propensity score model of treatment predicted a participant’s probability of
receiving a particular treatment given the observed participant factors via a multinomial
logistic regression with the five treatment groups as the outcome. The model produces
probabilities of receiving each of the five treatments, which sum to 1.00, for each
participant. Participants are then weighted by the inverse of the predicted probability of
the treatment that they actually received. Stabilized weights were calculated by
multiplying the inverse of the predicted probabilities of receiving the observed treatment
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by the observed marginal probabilities of receiving this treatment64. Selection of
covariates included was based on the minimal sufficient adjustment set from the DAG
(Figure 2.3), which were the baseline values of age, chronic pain, sleep disorders,
depression status, GDS score, any other psychiatric conditions except for depression, and
cognitive status. Chronic pain is not directly measured in the UDS, thus NSAIDs or
opioid medication use was used as a surrogate for chronic pain. Additionally, sleep
disorder variables were not included in the model due to the fact of heavy missingness
(sleep disorder data have been collected in the UDS only since March 2015).
The propensity score model of censoring predicts the probability of being
censored given the observed covariate values at baseline via a binary logistic regression
with censoring as the outcome. Covariates adjusted in this model are baseline
characteristics that we believed to be associated with being censored. Specifically, sex,
age, years of education, race, smoking, alcohol abuse, history of TBI, Parkinson’s disease,
hypertension, diabetes, high cholesterol, stroke, cardiovascular disease, chronic pain,
depression status, other psychiatric conditions and cognitive status were included in the
model. Stabilized weights were calculated by multiplying the inverse of the predicted
probabilities of being censored given the observed covariates values by the observed
marginal probabilities of being censored64.
The joint weights for balancing the overall subject baseline characteristic
distributions are computed by multiplying the stabilized weights for treatment and the
stabilized weights for censoring65. The joint weights are applied to the original cohort to
obtain a pseudo-cohort, or “weighted cohort”. In the weighted cohort, the overall
measured baseline characteristic distributions are balanced among the treatment groups.
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Such balance of measured baseline characteristics mimics a randomized clinical trial, in
which the probabilities of being assigned to any treatment arm are independent of
confounding variables, and the probabilities of being censored are independent as well.
The use of both weights jointly adjusts for both confounding at baseline and selection
bias during follow-up. Standardized mean differences between each treatment group and
the control group were calculated to assess the effectiveness of weighting.
A weighted Cox Proportional Hazards regression with antidepressant treatment
status as the only predictor in the model was performed to estimate the marginal effects
of antidepressants on the risk of developing dementia. The proportional hazards
assumption was checked by incorporating an interaction term of treatment by time in the
model.

2.2.9.3. Sensitivity Analyses
Three sensitivity analyses were conducted to assess the robustness of the main
analysis results. Sensitivity Analysis One used a restricted cohort with participants who
had not reported a diagnosis of depression or any other psychiatric conditions at the
baseline visit. All other analysis procedures remained the same as the main analysis. The
aim of Sensitivity Analysis One was to determine if the estimates in the main analysis
were impacted by confounding by indication, where the observed effect of the
medications is actually due to the pre-existing psychiatric conditions.
Sensitivity Analysis Two further includes ApoE ε4 status in the IPW model in
addition to the covariates adjusted in the IPW model in the main analysis. All other
analysis procedures remained the same as the main analysis. There is no evidence that
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ApoE ε4 status is related to antidepressant use. However, ApoE ε4 carriers are at greater
risk of developing Alzheimer’s disease compared with others66, and it has been
hypothesized that depression may occur during the preclinical phase of the disease67. The
purpose of the Sensitivity Analysis Two was to determine if ApoE ε4 status would
influence the estimates even though it was not hypothesized to be a confounder in the
pathway between antidepressant use and dementia.
Sensitivity Analysis Three used time-varying treatment instead of the fixed
treatment at the index visit. Changes between any treatment groups, including change
from one class to another, users to non-users or vice versa, were allowed. Participants’
baseline characteristics were balanced using the IPW. A Cox Proportional Hazards
regression with treatment as the time-varying covariate in the model was performed. The
aim of Sensitivity Analysis Three was to determine if the estimates in the main analysis
were impacted by the potential treatment regimen changes in later UDS visits.

2.3. Results
2.3.1. Descriptive Summaries
Participant characteristics at study baseline (i.e., the visit prior to the index visit)
are summarized in Table 2.2. Briefly, approximately 75% of the included subjects were
antidepressant-naïve, 14.4% of the subjects initiated SSRI use, 2.3% of the subjects
initiated SNRI use, 5.4% of the subjects initiated AA use, and 2.9% of the subjects
initiated TCA use. In total 645 out of 4302 participants (15.0%) were diagnosed with
incident dementia during follow-up. Treatment groups had higher proportions of
participants who developed dementia (26.7%, 18.2%, 19.2% and 16.8% for SSRIs,
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SNRIs, AAs and TCAs respectively) compared to the control group (12.3%). SSRI, SNRI
and AA users were estimated to have shorter median dementia-free-survival-times (2.7,
2.2, and 3.0 years for SSRIs, SNRIs, and AAs respectively) compared to the non-user
group (3.1 years). However, the diagnoses may not occur on the visit date thus the
dementia-free-survival times may be overestimated.
Mean baseline ages across the five groups were similar; the SNRI group had the
lowest mean baseline age and the AA group had the highest (Table 2.2). Regarding the
use of pain medications, SNRI users, AA users, and TCA users had higher proportions of
subjects who reported using NSAIDs or opioid medications compared to controls and
SSRI users. Psychiatric disorders, including depression and any other psychiatric
conditions, were in general more common among the antidepressant users (SSRIs, SNRIs,
AAs, and TCAs) than among the controls. Antidepressant users also tended to have
higher burden of depressive symptoms compared to the controls, based on the Geriatric
Depression Scale (Table 2.2). Even though there is not much difference regarding the
standard CDR sum of boxed across the groups, the control group had more participants
with normal cognition at baseline, while the antidepressant groups had more participants
with MCI at baseline. Hence, the distributions of the risk factors for dementia are not
balanced across groups. In other words, the treatment groups and control group are not
exchangeable.
Table 2.3 summarizes the baseline characteristics for the weighted cohort
(pseudo-cohort). In the weighted cohort, the risk factors for dementia at baseline were
distributed with good balance across the five groups in general. The SMDs of the
baseline risk factor values between each treatment group and the control group in the
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observed cohort are larger than 0.1 in general, indicating that the baseline risk factor
distributions are not comparable between each antidepressant group and the control group.
In the weighted cohort, the SMDs between each antidepressant group and the control
group are significantly reduced, suggesting balance across groups (Figure 2.4).

2.3.2. Main Analysis
Kaplan-Meier curves (Figure 2.5) and the Log-Rank test results showed that the
users of any antidepressant had significantly shorter median dementia-free-survival-times
compared to the control group (P-values<.0001). Among the antidepressant classes, SSRI
users had significantly shorter dementia-free-times compared to other antidepressant
users (P-values <.0001). There were no significant pair-wise differences among SNRI
users, AA users, and TCA users.
A weighted Cox Proportional Hazards regression model with antidepressant
treatment as the only predictor in the model was performed. Subjects who reported using
SSRIs, SNRIs, AAs, and TCAs at the index visit were estimated to have 2.04 (1.69-2.48),
2.10 (1.33, 3.31), 1.46 (1.05, 2.03) and 1.58 (1.04, 2.41) times the hazard of developing
dementia compared to subjects who did not report using any antidepressants at the index
visit, respectively. In other words, antidepressant users progressed to dementia more
quickly compared to the non-users. All estimated effects were significant at the 0.05
significance level. There is no evidence that the proportional hazards assumption was
violated (P-value=0.5387).
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2.3.3. Sensitivity Analyses
The point estimates for hazard ratio obtained from Sensitivity Analysis One,
where only participants who did not report a psychiatric diagnosis were included,
remained consistent with the main analysis in general, indicating that the estimates were
not sensitive to confounding by indication. In Sensitivity Analysis Two, where ApoE ε4
status was included in the propensity score model, the point estimates of a hazard ratios
remain consistent with the estimates in the Main Analysis. However, the estimated
confidence intervals in Sensitivity Analysis One and Sensitivity Analysis Two for AA
users and TCA users contains the null hazard ratio one. This was likely due at least in
part to the reduced sample size, because ApoE ε4 genotyping was unavailable for 7.2%
of participants. Sensitivity Analysis Three, which allowed treatment status to vary over
time, also generated consistent estimated hazard ratios compared to estimates in the Main
Analysis.

2.4. Discussion
In this study, we found that all antidepressant classes investigated increased the
hazard for dementia. SNRIs increase the levels of serotonin and norepinephrine in brain,
and both chemicals have been reported to enhance cognitive functions68,69, but in this
analysis SNRI use was associated with the shortest dementia-free-time. A possible
explanation is that SNRIs may increase the risk of dementia via hypertension as a
mediator. It is known that SNRIs may increase users’ blood pressure64,70, and
hypertension has been reported as a risk factor for vascular dementia and Alzheimer’s
dementia71. In this study, SNRI users had a higher proportion of participants reporting
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hypertension at baseline (64.7% for SNRI users versus 61.1% for SSRI users, 62.0% for
AA users, 59.4% for TCA users and 58.1% for controls). Hence, the SNRI users may
have higher risk of dementia at least in part because of the increased high blood pressure.
Alternatively, if SNRI treatment is related to the presence of preclinical
neurodegenerative disease (i.e., it is a result of reverse causality), this could explain the
association.
The underlying biological mechanism for increased dementia risk in SSRI users
remains unclear22. A possible explanation is that there might be a pathway between
SSRIs and dementia through zinc. An animal study has found upregulation of the GPR39
Zn2+-sensing receptor protein level after SSRI treatment72. Imbalance in zinc levels may
lead to neurofibrillary tangles, which is believed to be a marker of Alzheimer’s disease
and cognitive impairment73, but further research on human subjects is still needed in
answering this question. Again, if SSRI treatment is related to the presence of preclinical
neurodegenerative disease, this could also explain the association.
In clinical practice, AAs are often prescribed for treating other health conditions
besides depression. For example, trazodone is the second most commonly prescribed
medication for treating insomnia74, and insomnia is a risk factor for dementia75. The link
between AA use and dementia may be through unrecognized and unmeasured
confounders like insomnia. TCAs are usually not prescribed as the first-line treatment for
the elderly because TCAs may cause more side effects compared to other agents76. These
side effects include blurred vision and drop in blood pressure when moving from sitting
to standing77, which may be linked with dementia via the risk of falls. As with SNRIs and

24

SSRIs, if treatment is related to the presence of preclinical neurodegenerative disease,
this could explain the association.
There are several strengths of this study. First, successful IPW in this study
reduces selection bias at baseline by creating a balanced pseudo-cohort, in which the
probability of receiving a certain antidepressant treatment is independent of the observed
baseline prognostic factors. Hence, the average causal effects of each antidepressant class
on the risk of dementia were estimated in this study. While we do not assume that all the
conditions for causal inference based on observational data were met fully in this study,
we think it is valuable to carefully consider the hypothesized causal model and to be
transparent about the assumptions we made. Second, all potential confounders would be
included in the propensity score model in a conventional approach, however this
approach has been proved inadequate32,33. In this study, a DAG was built to identify the
minimal sufficient set for confounder adjustment. The DAG reduces the number of
parametric assumptions needed for this study compared to the number of parametric
assumptions needed in a conventional approach.
This study has some limitations. First, we did not control for all sources of
confounding. For example, we were not able to control well for confounding by
depression severity. Also, due to the inconsistent data collection protocols over time,
some important variables, like those documenting sleep disorders, were only collected for
UDS version 3, which was implemented in 2015, and are not available for UDS visits
prior to this new implementation. This leads to missingness on some major potential
confounders, such as sleep apnea history, REM sleep behavior disorder history, and
insomnia history. Furthermore, participants’ treatment groups are fixed at the index visit,
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regardless of any treatment regimen change in later visits. Change of antidepressant
treatment may indicate depression progression or medication resistance, but these issues
were largely ignored in this study. However, the sensitivity analysis that allowed
participants to change medications did not provide evidence that our main results were
due these factors. Another limitation is that the measurement of treatment is not ideal. For
example misclassification of treatment is possible given the long gap between two visits;
also there is no information about dosage or length of treatment. Drug-drug interaction
was not investigated. It is common that the elderly may simultaneously take multiple
medications given the complex health conditions associated with aging, but the
possibility of drug-drug interaction was not considered for this study. We also cannot
exclude the possibility of reverse causality78, where preclinical neurodegenerative disease
causes depression, which causes antidepressant initiation, which induces the association
between antidepressant use and dementia. Studies with decades of follow-up, where
incident cases that arise in the first pre-determined number of years of treatment are
excluded, are needed to test the reverse causality hypothesis79. Finally, we could not
examine the effects of individual antidepressant medications or conduct proper
comparative effective research due to sample size limitations.

2.5. Conclusion
In this study, Cox Proportional Hazard Regression with Inverse Probability
Weighting was performed to evaluate the effects of different antidepressant classes on the
risk of dementia. Significant causal effects of SSRIs, SNRIs, AAs and TCAs on the risk
of dementia were observed at the 0.05 significance level. In general, the estimates were
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not sensitive to confounding by indication of psychiatric disorders, genetic risk due to
ApoE ε4, or treatment regime switches in later visits.
All medications carry some risk of side effects that must be weighed against the
therapeutic benefit of the medications. For depressed elderly, antidepressant therapies are
important for maintaining quality of life. The question of whether their use causes an
increased risk of dementia causing diseases remains open, and the answer is important.
However, it is clearer is that the use of these antidepressant classes appears to hasten the
onset of dementia diagnosis in this population.
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Table 2.1. Antidepressant Classifications and Generic Drug Names
Classification
SSRI1

Generic Drug Name
fluoxetine, paroxetine, sertraline, citalopram, escitalopram,
vilazodone
2
SNRI
duloxetine, venlafaxine, desvenlafaxine, levomilnacipran
AA3
trazadone, mirtazapine, vortioxetine, bupropion, nefazodone
4
TCA
imipramine, nortriptyline, amitriptyline, doxepin, desipramine,
amoxapine, protriptyline, trimipramine
1
Selective serotonin reuptake inhibitors
2
Serotonin and norepinephrine reuptake inhibitors
3
Atypical antidepressants
4
Tri-cyclic antidepressants
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Table 2.2. Subject Characteristics at Baseline for the Observed Cohort
None
3225 (75.0)
77.5 ± 7.3
1430 (44.3)
410 (12.7)
0 (0, 1)
110 (3.4)
0 (0, 0.5)

SSRI1
619 (14.4)
76.1 ± 7.2
279 (45.5)
274 (44.3)
1 (0, 3)
60 (9.7)
0.5 (0, 1)

SNRI2
99 (2.3)
74.8 ± 6.9
51 (51.5)
51 (51.5)
2 (0, 4)
6 (6.1)
0 (0, 1)

AA3
234 (5.4)
77.1 ± 7.9
123 (52.6)
90 (38.6)
1 (0, 2)
19 (8.1)
0 (0, 0.5)

TCA4
125 (2.9)
76.7 ± 8.2
68 (54.4)
35 (28.2)
1 (0, 2)
4 (3.2)
0 (0.5)
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N
Age (year)
Pain meds5
Depression
GDS6
Psychiatric7
CDR8
Cognition
Normal
2442 (75.7)
336 (54.3)
63 (63.6)
152 (65.0)
91 (72.8)
9
Impaired
148 (4.6)
67 (10.8)
10 (10.1)
11 (4.7)
3 (2.4)
MCI10
635 (19.7)
216 (34.9)
26 (26.3)
71 (30.3)
31 (24.8)
ApoE ε4 +
871 (29.0)
189 (33.4)
32 (37.2)
71 (31.6)
31 (27.2)
Dementia incidence
396 (12.3)
165 (26.7)
18 (18.2)
45 (19.2)
21 (16.8)
Time to dementia (year)
3.1 (1.9, 5.5)
2.7 (1.2, 4.9)
2.2 (1.2, 4.8)
3.0 (1.6, 4.8)
3.3 (1.4, 5.2)
Note: Mean ± S.D. are reported for normally-distributed continuous variables. Median (Q1, Q3) are reported for non-normallydistributed variables. Frequency (%) are reported for categorical variables.
1
Selective serotonin reuptake inhibitors
2
Serotonin and norepinephrine reuptake inhibitors
3
Atypical antidepressants
4
Tri-cyclic antidepressants
5
NSAIDs or opioid medications
6
Total Geriatric Depression Scale Score
7
Any other psychiatric conditions except for depression, including post-traumatic stress disorder, bipolar, schizophrenia, anxiety,
obsessive-compulsive disorder or developmental neuropsychiatric disorder
8
CDR sum of boxes
9
Impaired but not MCI
10
Mild Cognitive Impairment

Table 2.3. Subject Characteristics at Baseline for the Weighted Cohort
None
3200
77.4 ± 7.3
1479 (45.9)
657 (20.5)
1 (0, 2)
162 (5.0)
0 (0, 0.5)

SSRI1
651
77.6 ± 7.6
305 (47.7)
146 (22.5)
1 (0, 2)
40 (6.2)
0 (0, 0.5)

SNRI2
100
76.9 ± 7.1
53 (51.6)
24 (24.3)
1 (0, 2)
5 (5.1)
0 (0, 0.5)

AA3
240
77.6 ± 7.8
108 (44.8)
54 (22.5)
1 (0, 2)
15 (6.0)
0 (0, 0.5)

TCA4
127
77.6 ± 8.1
55 (43.3)
24 (19.2)
1 (0, 2)
4 (3.2)
0 (0, 0.5)
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N
Age (year)
Pain meds5
Depression
GDS6
Psychiatric7
CDR8
Cognition
Normal
2254 (70.4)
464 (71.3)
74 (73.6)
167 (69.4)
94 (73.7)
9
Impaired
188 (5.9)
39 (6.0)
6 (6.3)
14 (5.7)
6 (4.6)
MCI10
758 (23.7)
148 (22.7)
20 (20.1)
60 (24.9)
28 (21.7)
Note: Mean ± S.D. are reported for normally-distributed continuous variables. Median (Q1, Q3) are reported for non-normallydistributed variables. Frequency (%) are reported for categorical variables.
1
Selective serotonin reuptake inhibitors
2
Serotonin and norepinephrine reuptake inhibitors
3
Atypical antidepressants
4
Tri-cyclic antidepressants
5
NSAIDs or opioid medications
6
Total Geriatric Depression Scale Score
7
Any psychiatric conditions except for depression, including post-traumatic stress disorder, bipolar, schizophrenia, anxiety, obsessivecompulsive disorder or developmental neuropsychiatric disorder
8
Standard CDR sum of boxes
9
Impaired but not MCI
10
Mild Cognitive Impairment

Table 2.4. Hazard Ratios (95% CIs) for Main Analysis and Sensitivity Analyses
Main Analysis
Sensitivity Analysis One1
Sensitivity Analysis Two2
Sensitivity Analysis Three3
SSRI
2.04 (1.69, 2.48)
1.93 (1.49, 2.51)
1.82 (1.48, 2.23)
2.78 (2.26, 3.42)
SNRI5
2.10 (1.33, 3.31)
2.56 (1.37, 4.75)
2.24 (1.39, 3.60)
3.01 (1.95, 4.64)
6
AA
1.46 (1.05, 2.03)
1.42 (0.89, 2.25)
1.36 (0.95, 1.93)
1.80 (1.23, 2.64)
TCA7
1.58 (1.04, 2.41)
1.53 (0.92, 2.54)
1.12 (0.68, 1.86)
1.67 (0.90, 3.12)
1
Restricted analysis on participants without any psychiatric disorders
2
Restricted analysis on participants with ApoE ε4 measurement and ApoE ε4 status was adjusted in the propensity score model
3
Analysis allows for time-varying treatment
4
Selective serotonin reuptake inhibitors
5
Serotonin and norepinephrine reuptake inhibitors
6
Atypical antidepressants
7
Tri-cyclic antidepressants
4
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Figure 2.1. Study Cohort Derivation Flowchart
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Figure 2.2. Illustration of Matching Process

Note: This figure is for illustrative purpose only. Participant information used for this
graph is not true information from the data.
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Figure 2.3. Directed Acyclic Graph for Assessing the Minimum Sufficient Adjustment Set
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Figure 2.4. Standardized Mean Difference Comparisons
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Figure 2.5. Kaplan-Meier Curves by Treatment Groups and Log-rank Tests between Treatment Groups for the Original (unweighted)
Cohort
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CHAPTER THREE. THE EFFECTS OF UNMEASURED SLEEP DISORDERS ON
THE RELATIONSHIP BETWEEN ANTIDEPRESSANT USE AND THE RISK OF
DEMENTIA

3.1. Introduction
In epidemiologic studies, causal effects of an exposure on an outcome are of
interest. Causation can be inferred in an ideal randomized trial, because randomization
will ensure the exchangeability between the exposed group and the unexposed group80.
However, since randomization is often not feasible, we are left with observational data
where the exposed group and the unexposed group are not always comparable to each
other34. It is common in observational studies that confounding is controlled by statistical
methods, but the potential uncontrolled confounding may still lead to distorted estimation
of the association between exposure and outcome. It is generally expected that
exchangeability and perfect adjustment of all confounders will not be true in
observational studies.
In Chapter Two, Inverse Probability Weighting methods were used to assess the
average causal effects of antidepressants on the risk of dementia using National
Alzheimer’s Coordinating Center (NACC) Uniform Data Set (UDS). A pseudo-cohort, in
which the prognostic factors for receiving a certain type of treatment were balanced
across groups, was constructed under the assumption that there was no unmeasured
confounding given the observed data. The impacts of antidepressants on the risk of
dementia were evaluated using the pseudo-cohort so that the causal effects could be
inferred. Nevertheless, the assumption that there are no unmeasured confounders may not
be true.
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There are several reasons why the assumption of no unmeasured confounding
may not be true. First, some hypothetical confounders for the association between
antidepressant use and dementia, including socio-economic status and physical activities,
are not measured in the UDS. Second, even for hypothetical confounders measured in the
UDS, some of them are not usable for the purpose of this study. For example, information
about sleep apnea, rapid-eye-movement behavior disorder (RBD), and insomnia is only
collected for the UDS version 3, which was implemented in March 2015. UDS visits
prior to the implementation of the UDS version 3 (September 2005-February 2015) did
not collect this information. In other words, these variables suffer from heavy
missingness.
Based on our hypothesized causal model, an ideal observational study that
evaluates the effects of antidepressants on the risk of dementia would include
measurements for age, sex, race, education, socio-economic status, smoking, alcohol
abuse, physical activities, traumatic brain injury (TBI), Parkinson’s disease, hypertension,
type 2 diabetes, high cholesterol, stroke, cardiovascular disease (CVD), chronic pain,
sleep disorders, depression status, any other psychiatric conditions except for depression
(for example anxiety etc.), cognitive status, anti-anxiety medication use, and ApoE ε4
allele status81,82 (see Figure 2.3). As mentioned previously, socio-economic status and
physical activities are not measured in the UDS, and sleep disorder variables suffer from
heavy missingness. Based on Figure 2.3, the minimal sufficient adjustment set includes
baseline age, chronic pain, sleep disorders, depression status, Geriatric Depression Scale
(GDS) score, any other psychiatric conditions except for depression (i.e. post-traumatic
stress disorder, bipolar, schizophrenia, anxiety, obsessive-compulsive disorder or
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developmental neuropsychiatric disorder), standard CDR sum of boxed, and cognition.
Unfortunately, sleep disorders could not be included in the analysis.
Failing to adjust for sleep disorders in the analysis may lead to inaccurate effect
estimates. For example, a series of studies have investigated the impact of sleep apnea on
cognition, and it is believed that sleep apnea is associated with cognitive dysfunctions83-85.
Similarly, studies suggest that Rapid Eye Movement Behavior Disorder (RBD) and
insomnia are associated with impaired cognition75,86-88. On the other hand, sleep disorders
are associated with antidepressant use. For example, SSRIs may cause insomnia89, and
trazodone, which is a type of atypical antidepressant, is often used for treating insomnia90.
In this study, the effects of sleep disorders as unmeasured confounders for the
association between antidepressant use and the risk of dementia were investigated. The
average causal effects of antidepressants on the risk of dementia adjusted for both
measured and unmeasured confounders were assessed.

3.2. Methods
In Chapter Two, the effects of different classes of antidepressant were estimated
assuming we controlled for all potential confounders. This assumption may not be valid
due to the omission of sleep disorders. Hence, in this Chapter, 1) a bias factor formula for
two binary unmeasured confounders is derived; 2) Monte Carlo Sampling is implemented
to estimate the distribution of the bias factor for each class of antidepressant; 3) the
effects of antidepressants on the risk of dementia are adjusted for both measured and
unmeasured confounders are estimated. Table 3.1 summarizes the confounder
adjustments status in this research.
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3.2.1. Formula of Bias Factor
For the purposes of this study, we limit our discussion to two binary unmeasured
confounders. Let X be the indicator for use of a certain class of antidepressant, Z be a
vector of controlled covariate values at baseline, 𝑈𝑈1 be the indicator for uncontrolled
confounder 1, and 𝑈𝑈2 be the indicator for uncontrolled confounder 2. Let 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 be the

estimated observed hazard ratio for a certain class of antidepressant that is adjusted for
the effects of the covariates in Z, but does not adjust for the effects of U. 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 can be

written as:

𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 =

𝜆𝜆0 (𝑡𝑡) · exp(𝛽𝛽(𝑋𝑋 = 1) + 𝛾𝛾𝒁𝒁)
𝜆𝜆0 (𝑡𝑡) · exp(𝛽𝛽(𝑋𝑋 = 0) + 𝛾𝛾𝒁𝒁)

= exp(𝛽𝛽)

Let 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 be the hypothetical hazard ratio for a certain class of antidepressant that

adjusted for the effects of both Z and U. 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 is the target parameter of interest in this
study, and it can be written as:
𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎

𝜆𝜆0 (𝑡𝑡) · exp(𝛽𝛽 ∗ (𝑋𝑋 = 1) + 𝛾𝛾 ∗ 𝒁𝒁 + 𝜔𝜔𝑼𝑼))
=
𝜆𝜆0 (𝑡𝑡) · exp(𝛽𝛽 ∗ (𝑋𝑋 = 0) + 𝛾𝛾 ∗ 𝒁𝒁 + 𝜔𝜔𝑼𝑼))

= exp(𝛽𝛽 ∗ )

Let 𝑃𝑃𝑋𝑋,𝑈𝑈1 ,𝑈𝑈2 denote the proportion of subjects for the specific 𝑈𝑈1 -𝑈𝑈2 stratum in group X=x.
For example, 𝑃𝑃1,1,0 is the proportion of subjects who reported using a certain class of
antidepressant X=1 and have condition 𝑈𝑈1 but not 𝑈𝑈2 .

The change in the hazard for the control group due to 𝑈𝑈1 and 𝑈𝑈2 , denoted as

∗
𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
, is a weighted average of the hazard ratios for strata of (𝑈𝑈1 = 0, 𝑈𝑈2 = 0), (𝑈𝑈1 =
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1, 𝑈𝑈2 = 0) , (𝑈𝑈1 = 0, 𝑈𝑈2 = 1) and (𝑈𝑈1 = 1, 𝑈𝑈2 = 1) in the control group using 𝑃𝑃0,0,0 ,

∗
𝑃𝑃0,1,0, 𝑃𝑃0,0,1, 𝑃𝑃0,1,1 as weights. 𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
can be written as:
∗
𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
=�

𝑈𝑈1

� exp(𝜔𝜔1 𝑈𝑈1 + 𝜔𝜔2 𝑈𝑈2 )𝑃𝑃0,𝑈𝑈1 ,𝑈𝑈2
𝑈𝑈2

= 𝑃𝑃0,0,0 + exp(𝜔𝜔1 )𝑃𝑃0,1,0 + exp(𝜔𝜔2 )𝑃𝑃0,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2 )𝑃𝑃0,1,1

Similarly, the change in the hazard for a certain class of antidepressant due to 𝑈𝑈1 and 𝑈𝑈2 ,
∗
denoted as 𝐻𝐻𝐻𝐻𝑡𝑡𝑡𝑡𝑡𝑡
, can be written as:
∗
=�
𝐻𝐻𝐻𝐻𝑡𝑡𝑡𝑡𝑡𝑡

𝑈𝑈1

� exp(𝜔𝜔1 𝑈𝑈1 + 𝜔𝜔2 𝑈𝑈2 )𝑃𝑃1,𝑈𝑈1 ,𝑈𝑈2
𝑈𝑈2

= 𝑃𝑃1,0,0 + exp(𝜔𝜔1 )𝑃𝑃1,1,0 + exp(𝜔𝜔2 )𝑃𝑃1,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2 )𝑃𝑃1,1,1

where ∑𝑈𝑈 means sum over all values of U.

∗
∗
Any difference between 𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
and 𝐻𝐻𝐻𝐻𝑡𝑡𝑟𝑟𝑟𝑟
can only be due to the differences in

the distributions of 𝑈𝑈1 and 𝑈𝑈2 between the treatment group and the control group.
Therefore, the change in hazard due to differences in 𝑈𝑈1 and 𝑈𝑈2 between the treatment

group and the control group can be written as:

∗
𝐻𝐻𝐻𝐻𝑡𝑡𝑡𝑡𝑡𝑡
𝑃𝑃1,0,0 + exp(𝜔𝜔1 )𝑃𝑃1,1,0 + exp(𝜔𝜔2 )𝑃𝑃1,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2 )𝑃𝑃1,1,1
𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 =
=
∗
𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑃𝑃0,0,0 + exp(𝜔𝜔1 )𝑃𝑃0,1,0 + exp(𝜔𝜔2 )𝑃𝑃0,0,1 + exp(𝜔𝜔1 + 𝜔𝜔2 )𝑃𝑃0,1,1

(Formula 1)

Hence, the observed HR adjusted for 𝑈𝑈1 and 𝑈𝑈2 , i.e. 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 , can be estimated by dividing
the Hazard Ratio that did not adjust for 𝑈𝑈1 and 𝑈𝑈2 , i.e. 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 , by the above derived bias
factor:

𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 =
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𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜
𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵

(Formula 2)

3.2.2. Monte Carlo Sampling
In this study, four bias factors need to be estimated: SSRI users relative to
controls, SNRI users relative to controls, AA users relative to controls, and TCA users
relative to controls. Monte Carlo Sampling was performed to estimate the distribution of
each bias factor.
The prior distribution of the HR for sleep apnea was obtained from a large
population-based retrospective matched-control cohort study using the Longitudinal
Health Insurance Database 2005 in Taiwan91. The study cohort comprised 1414 subjects
with sleep apnea and 7070 subjects without sleep apnea who were matched with the sleep
apnea subjects on sex, age and index-year. A Cox Proportional Hazards regression model
was performed to estimate the 5-year dementia-free survival rates after adjusting for
potential confounders. The investigators concluded that subjects with sleep apnea have
1.70 (95% CI: 1.26-2.31) times the hazard of developing dementia within 5 years of
diagnosis compared to subjects without sleep apnea after adjusting for potential
confounders.
The prior distribution of the HR for RBD on the risk of dementia was obtained
from a population-based cohort study investigating the impacts of RBD on the risk of
MCI, dementia or Parkinson’s disease87. Subjects were randomly selected from the 70-89
years old residents of Olmsted County, Minnesota, USA to participant in the Mayo Clinic
Study of Aging. The study cohort consists of 44 subjects with probable RBD and 607
subjects without probable RBD. A Cox Proportional Hazards regression model was
performed to estimate the adjusted hazard ratio and the corresponding 95% confidence
intervals after adjusting for age, sex, education and medical comorbidities. The subjects
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were followed prospectively for a median of 3.8 years. Subjects with probable RBD had
2.2 (95% CI: 1.3-3.9) times the hazard of MCI/PD (no subject developed dementia by the
end of the study) compared to subjects without probable RBD.
The prior distributions for the prevalence of each sleep apnea-RBD stratum were
obtained from the NACC UDS population. The sleep apnea and RBD variables are only
available for UDS version 3, thus these two potential confounders could not be included
into the main analysis in Chapter Two. However, we can still use the available
information as the prior distributions for the prevalence of sleep apnea and the prevalence
of RBD.
Table 3.2 summarizes the prior distribution specification for each parameter used
for estimating the empirical distributions of the 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 . Normal distributions for the log
hazard ratios 𝜔𝜔1 and 𝜔𝜔1 were used. Dirichlet distributions for the proportion for each

sleep apnea-RBD stratum among the certain treatment group were used. Distributions for
the observed estimated model coefficients were taken from the Main Analysis in Chapter
Two to add random sampling errors into the Monte Carlo analysis.
We drew 10,000 samples of 𝜔𝜔1 and 𝜔𝜔1 respectively from the specified Normal

distributions, and 10,000 sets of samples of treatment prevalence across the sleep apneaRBD stratum. Under Formula 1, 10,000 bias factors were computed for each treatment

group respectively. Furthermore, we drew 10,000 samples of 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 for each treatment
group respectively from the Normal distributions using the distributions for the observed

estimated model coefficients. Thus, we were able to calculate 10,000 𝐻𝐻𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 for each

class of antidepressant. The calculated 𝐻𝐻𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 formed an empirical distribution of 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎

for each class of antidepressant, and these empirical distributions are symmetrical bell43

shaped distributions (see Figure 3.1). The mean of each empirical distributions was
computed as the point estimate of 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 . The 2.5th and 97.5th percentiles were found as

the lower confidence limit and upper confidence limit, respectively.

3.3. Results
In this study, sleep apnea and RBD were identified as the two sources of
unmeasured confounding. The estimated mean of 𝐻𝐻𝐻𝐻𝑎𝑎𝑎𝑎𝑎𝑎 and the 95% CI for each

treatment group are displayed in Table 3.3 with a comparison of 𝐻𝐻𝐻𝐻𝑜𝑜𝑜𝑜𝑜𝑜 from the Main
Analysis in Chapter Two.

In Chapter Two, a weighted Cox Proportional Hazards regression model with
antidepressant treatment as the only predictor in the model was performed. Subjects
reported using SSRIs, SNRIs, AAs, and TCAs at the index-visit were estimated to have
2.04 (1.69-2.48), 2.10 (1.33, 3.31), 1.46 (1.05, 2.03) and 1.58 (1.04, 2.41) times the
hazard of developing dementia compared to subjects who did not report using any
antidepressants at the index-visit, respectively. All estimates were significant at the 0.05
level.
In this Chapter, after adjusting for the unmeasured effects of sleep apnea and
RBD, subjects who reported using SSRIs, SNRIs, AAs and TCAs at the index-visit were
estimated to have 1.95 (1.59, 2.36), 1.85 (1.11, 2.91), 1.34 (0.93, 1.87) and 1.63 (1.04,
2.43) times the hazard of developing dementia compared to subjects who did not report
using any antidepressant use at index-visit, respectively. All estimates are still significant
at the 0.05 level. The estimates adjusted for sleep apnea and RBD are pulled towards the
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null for SSRI, SNRI and AA users, but the estimates adjusted for sleep apnea and RBD
remained approximately the same for the TCA users (Figure 3.1).

3.4. Discussion
In this study, sleep apnea and RBD were identified as the two major sources of
unmeasured confounding in our previous analyses of antidepressant use and dementia
risk. The magnitude of bias caused by the effects of sleep apnea and RBD were estimated
though Monte Carlo sampling. The hazard ratios adjusted for the effects of sleep apnea
and RBD were computed by dividing the hazard ratios unadjusted for the effects of sleep
apnea and RBD by the estimated magnitudes of bias.
In the Main Analysis in Chapter Two, we ignored the effects of sleep apnea and
RBD, thus the distribution of sleep apnea or RBD may not be comparable across
treatment groups, hence the estimated effects of antidepressant on the risk of dementia
may be distorted. We hypothesize that the results from the Monte Carlo analysis
improved the estimates from Chapter Two towards the “true” direction by accounting for
the effects introduced by sleep apnea and RBD.
The hazard ratios adjusted for sleep apnea and RBD and the corresponding 95%
confidence intervals were shifted toward the null for the SSRI, SNRI, and AA users, but
the point estimate of the hazard ratio adjusted for sleep apnea and RBD for the TCA users
is slightly shifted away from the null (the 95% confidence interval remained
approximately the same). The estimation of the effect of TCA on the risk of dementia
was not sensitive to the omission of sleep apnea and RBD. In other words, sleep apnea
and RBD may not be a confounder between TCA use and dementia.
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This study has some limitations. First, prior distribution specifications for
parameters are based on a single study for each parameter. While the studies were
population-based, the populations studied may not be comparable to the NACC UDS
population. An improvement could be obtaining prior distribution parameters by
conducting meta-analyses. Second, proportions for each sleep apnea-RBD stratum across
the treatment groups were obtained from the UDS version 3, which was initiated after
2015. Compared with the study population in this dissertation, participants in the UDS v3
subgroup were in general younger, had higher proportions for psychiatric disorders
(including depression and any other types) and had higher proportions of MCI diagnosis
at baseline. Thus, this subgroup was not a representative sample of the study population
in this research. Finally, this study was restricted to two binary unmeasured confounders,
hence insomnia is not discussed in this study. However, insomnia may be an important
confounder for the association between antidepressant use and risk of dementia and
should be addressed.

3.5. Conclusion
In this Chapter, the effects of sleep apnea and RBD as uncontrolled confounders
between the association between antidepressant use and the risk of dementia were
investigated. A bias factor formula for two binary unmeasured confounders was derived.
Monte Carlo analysis was implemented to estimate the distribution of bias factor for each
class of antidepressant. The effects of antidepressants on the risk of dementia adjusted for
both measured and unmeasured confounders were estimated. Sleep apnea and RBD bias
the estimation toward the null for the effect of SSRI, SNRI or AA on the risk of dementia.
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Sleep apnea and RBD may not be a confounder on the pathway between TCA use and
developing dementia. For future studies, meta-analysis could be conducted to obtain the
prior distributions for parameters. Additionally, the effects of insomnia and other types of
sleeping disorders can be investigated.
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Table 3.1. Confounder Adjustment Status
All Hypothetical
Confounders
Demographics Age
Sex
Race
Education
SES1
Life Styles
Smoking
Alcohol abuse
Physical activities
Comorbidity
TBI2
and
Parkinson
Medication
Hypertension
History
Type 2 diabetes
High cholesterol
Stroke
CVD3
Chronic pains
Sleep disorders
Depression
GDS score4
Other psychiatric
disorders
CDR sum of boxes
Cognition status
Anti-anxiety
medications
Genetics
ApoE ε4 status
1
Socio-economic Status
2
Traumatic Brain Injury
3
Cardiovascular Disease
4
Geriatric Depression Scale score

UDS
Availability
√
√
√
√

Minimal
Sufficient
Set
√

Chapter
Two

Chapter
Three

√

√

√
√
√
√
√

√
√
√
√

√
√
√
√
√

√
√

√
√

√
√

√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
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√

Table 3.2. Parameter Prior Distribution Specifications
𝛃𝛃𝒐𝒐𝒐𝒐𝒐𝒐 5
𝝎𝝎𝟏𝟏 6
𝝎𝝎𝟐𝟐 7
𝑷𝑷𝑿𝑿,𝑼𝑼𝟏𝟏 ,𝑼𝑼𝟐𝟐 8
Control
-Dirichlet (1926,350,34,17)
1
9
SSRI
N (0.71, 0.10)
Dirichlet (331, 87, 6, 7)
SNRI2
N (0.74, 0.23) N (0.53, 0.15) N (0.79, 0.28) Dirichlet (71, 32, 0, 5)
AA3
N (0.38, 0.17)
Dirichlet (135, 41, 3, 6)
TCA4
N (0.46, 0.21)
Dirichlet (40, 8, 1, 0)
1
Selective serotonin reuptake inhibitors
2
Serotonin and norepinephrine reuptake inhibitors
3
Atypical antidepressants
4
Tri-cyclic antidepressants
5
Observed beta coefficient from the Main Analysis in Chapter Two
6
Log hazard ratio for sleep apnea from literature
7
Log hazard ratio for RBD from literature
8
Prevalence of each sleep apnea-RBD stratum in the UDS for a certain treatment group
9
Normal distribution
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Table 3.3. Estimated Bias-factor Adjusted and Observed Hazard Ratios for Dementia
𝑯𝑯𝑯𝑯𝒐𝒐𝒐𝒐𝒐𝒐
SSRI
2.04 (1.69, 2.48)
2
SNRI
2.10 (1.33, 3.31)
AA3
1.46 (1.05, 2.03)
4
TCA
1.58 (1.04, 2.41)
1
Selective serotonin reuptake inhibitors
2
Serotonin and norepinephrine reuptake inhibitors
3
Atypical antidepressants
4
Tri-cyclic antidepressants
1
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𝑯𝑯𝑯𝑯𝒂𝒂𝒂𝒂𝒂𝒂
1.95 (1.59, 2.36)
1.85 (1.11, 2.91)
1.34 (0.93, 1.87)
1.63 (1.04, 2.43)

Figure 3.1. Observed and Bias-factor Adjusted Hazard Ratio Distributions
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CHAPTER FOUR. RE-ESTIMATING THE EFFECTS OF ANTIDEPRESSANT USE
ON THE RISK OF DEMENTIA USING MULTI-STATE MARKOV CHAIN

4.1. Introduction
The current recommendation for treating major depressive disorders is to use
antidepressants over prolonged periods to relieve symptoms and prevent further episodes
of depression92,93. The initial selection of an antidepressant medication is primarily
dependent on the anticipated side effects, the safety or tolerability of these side effects for
the patient, the pharmacological properties of the medication, and other factors such as
patient’s response to previous treatment, patient preference, insurance formulary, and
cost94. However, psychiatrists may suggest changing the treatment regimen if poor
efficacy or intolerance is observed93. Additionally, patients may discontinue
antidepressant treatment for various reasons95.
In previous chapters, the effects of antidepressant medication on the hazard of
developing dementia were assessed assuming participants adhere to the initial treatment
assignment. To briefly summarize, antidepressant use was fixed at the index-visit and
intent-to-treat analysis was used. A Cox Proportional Hazards regression model with
Inverse Probability Weighting was then performed to assess the hazard for developing
dementia.
There are important assumptions made in the previous Cox regression analyses.
First, participants were assumed to stick with the treatment assignment at the index visit
until a certain event of interest occurs. Second, the hazards for developing dementia were
assumed to be proportional over time. Third, participants were assumed to make only one
transition from the baseline cognitive status to a certain event of interest. In other words,
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the potential transitions among cognitive states prior to the occurrence of a certain event
were ignored. Furthermore, we made the assumption that participants could not recover
from mild impairment.
In practice, participants in the National Alzheimer’s Coordinating Center are
assessed annually. Cognitive status, medication use, physical and neurological
examinations, and medical history are recorded at each assessment. Participants may
switch or discontinue antidepressant treatments. Participants’ characteristics (e.g.,
comorbidities, medication use, demographic information, etc.) may also change over time.
Such changes may lead to time-varying hazards for developing dementia. In addition,
participants may transition among different cognitive stages, such as normal cognition
and mild cognitive impairment (MCI), before developing dementia. Participants may die
from other causes, such as cancer, cardiovascular diseases, etc., before developing
dementia, and such deaths will prevent participants from developing dementia. In the
situation where the hazard of a certain health outcome is varying over time and the
outcome may occur more than once, Markov models will be particularly useful96.
In this study, we assessed the association between each class of antidepressant
and the probability of dementia while accounting for the potential time-varying risks for
dementia and the potential transitions among different cognitive stages before finally
developing dementia. To achieve this goal, multi-state Markov models based on
multinomial logistic regression were constructed.
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4.2. Methods
4.2.1. Data Source and Subjects
Subjects of this study are those who participated in the annual assessment at the
National Alzheimer’s Coordinating Center (NACC), as known as the Uniform Data Set
(UDS)97. The detailed description of the NACC UDS can be found in Chapter Two.
Briefly, the NACC UDS was collected by trained clinicians and clinical practitioners
from participants and their co-participants during in-person office visits following a
standard data collection protocol. The UDS includes subjects with various levels of
cognitive status: dementia caused by different reasons, different levels of cognitive
impairment, and intact cognition61. As of September 2018, among all the UDS subjects,
35.1% were diagnosed with normal cognition, 4.3% were impaired but not MCI, 17.2%
were diagnosed with MCI, and 43.4% had been diagnosed with dementia.
The following exclusion criteria were implemented for the purpose of this study.
After applying these exclusion criteria, 11,939 subjects remained in the study (Figure 4.1).
1) prevalent dementia patients at the initial UDS visit;
2) prevalent antidepressant users at the initial UDS visit;
3) participants with only one UDS visit;
4) participants who were younger than 65-years-old at the initial UDS visit;
5) MAOI users or combination users at the index-visit.

4.2.2. Measurements
The methods used for measuring antidepressant use, cognitive status and other
covariates for adjustment remain the same as the methods used in Chapter Two. Briefly,
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participants were asked about their medication use within two-week window prior to the
current UDS visit. The four classes of antidepressants identified are selective serotonin
reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs),
tri-cyclic antidepressants (TCAs) and atypical antidepressants (AAs).

Based on

clinicians’ assessments, cognitive status is classified into four levels: normal cognition,
mild cognitive impairment (MCI), impaired but not MCI, and dementia. A series of
cognitive or behavioral symptoms should be met for patients to be defined as any of the
four levels of cognitive status61. Based on the DAG constructed in Chapter Two,
covariates for adjustment included age, chronic pain, depression status, GDS score,
psychiatric conditions other than depression, standard CDR sum of boxes, and the
cognitive status. ApoE ε4 status was not included in the models since the results from the
Sensitivity Analysis Two in Chapter Two indicated that ApoE ε4 status is not a
confounder on the pathway between antidepressant use and dementia development.
Subjects’ treatment values, covariates values and cognitive status were assessed at every
UDS visit.

4.2.3. Statistical Analysis
To evaluate the effects of different classes of antidepressants on the risk of
dementia while accounting for the time-varying treatment and time-varying confounders,
a multi-state Markov chain was implemented. One limitation of the estimations in
Chapter Two was that treatment assignment and confounders for adjustment were fixed at
the treatment UDS visit and baseline UDS visit respectively, regardless of the treatment
switch in later visits or the existence of time-dependent confounders. Although we
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conducted a sensitivity analysis using time-varying treatment, which supported our main
results, we could not accommodate time-varying confounders. This issue can be
accommodated by the multi-state Markov chain. Additionally, competing risks for the
main outcome of interest, in this case death before dementia, can also be addressed by
this approach, along with back transitions.
A multi-state Markov chain with three transient states (normal cognition,
impaired but not MCI, and MCI) and two absorbing states (dementia and death prior to
dementia) was constructed to estimate the probabilities of moving from a prior state to a
current state. Subjects may move back and forth between any two of the transient states
in a transition cycle, but once a subject enters an absorbing state, the subject will never
exit (Figure 4.2). Although participants may die after developing dementia, those
transitions were not of interest in this study. A participant’s follow-up ended with entry
into an absorbing state or their last active UDS visit. A subject-specific shared random
effect, which was assumed to have normal distribution, was included in the models to
account for the within-subject correlation98.
Specifically, a series of three polytomous logistic regression models were built to
model log-odds of the one-step transitions between any two transient states or the onestep transitions between a transient state and an absorbing state, conditioned on the prior
(transient) state:
logit �𝑷𝑷𝒑𝒑,𝒄𝒄 (𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 1|𝒙𝒙𝑖𝑖 , 𝒛𝒛𝑖𝑖 , 𝒖𝒖𝑖𝑖 )� = 𝜶𝜶𝒑𝒑,𝒄𝒄 + 𝜷𝜷𝑇𝑇𝑝𝑝,𝑐𝑐 𝒙𝒙𝑖𝑖 + 𝜸𝜸𝑇𝑇𝑝𝑝,𝑐𝑐 𝒛𝒛𝑖𝑖 + 𝒖𝒖𝑖𝑖

Here, x is a vector of indicators for treatment; z is a vector of covariates for adjustment,
and u is the subject-specific shared random effect. The subscript i refers to subject i, p
refers to the prior state, and c refers to the current state. For instance, if the prior state is
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normal cognition and the current state is MCI, 𝑷𝑷𝒑𝒑,𝒄𝒄 represents the probability of transition
from normal cognition to MCI versus remaining in normal cognition, given values of x, z

and u. All transitions are assumed to occur on the visit date. Any transitions among the
transient states between the visits, which are not observed, are ignored.
To evaluate the predicted time for transition from one particular state to another, a
Markov cohort simulation analysis was conducted using the estimated transition
probabilities based on the fitted models for the one-step transitions. Times spent on
transitions from baseline normal cognition to dementia and transitions from baseline MCI
to dementia were estimated for each class of antidepressant assuming different baseline
ages and different baseline depression statuses, while controlling for the effects of other
covariates.
For the purpose of this study, transitions from and to “impaired but not MCI”
were included in the model, but these results are of limited interest since the “impaired
not MCI” category is quite heterogeneous. A diagnosis of “impaired but not MCI”
denotes clinical impairment on cognition but does not meet criteria for MCI or dementia.
The underlying causes of this impairment are unknown, and may include medical
conditions, psychiatric conditions, and medication-induced cognitive dysfunction. Thus,
we included this diagnosis as a state in order not to exclude data from these visits.
However, it is not clear to what type of person these results would generalize. Therefore,
these results are reported but not discussed in detail. All analyses were performed using
PROC NLMIXED and PROC IML in SAS/STAT 9.4.
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4.3. Results
Participants’ had a median of four annual assessments, with an interquartile range
of 2 to 7 visits. The median days between assessments was 378 days, with an interquartile
range of 358 to 427 days. For purposes of describing the sample, participant
characteristics were fixed at the initial UDS visit, hence no participants were yet taking
antidepressants (Table 4.1). At the initial visit, the average age for this cohort of
participants was 76-years-old, and more than one-third (36.8%) of these participants
reported using pain medications. Additionally, about one fifth of the participants had at
least one psychiatric disorder (16.6% had depression and 4.1% had any other psychiatric
disorder except for depression). Most of the participants had normal cognition at entry
(63.9%), while 30.1% of the participants had MCI.
During the study period, 1741 participants (14.6%) made at least one transition
from normal cognition to MCI, 235 participants (2.0%) transitioned from normal
cognition to dementia, and 773 participants (6.5%) died with normal cognition.
Additionally, 1897 participants (15.9%) transitioned from MCI to dementia, and 534
participants (4.5%) died with MCI. Detailed one-step transition distributions are
summarized in Table 4.2. In general, participants were most likely to remain in the
transient state where they were previously observed. Transitions to dementia were most
likely to occur from MCI. Back transitions from impaired but not MCI to normal and
from MCI to normal were relatively common.
Transitions of interest are marked bold in Table 4.3. For transitions from normal
cognition to MCI, SSRIs, SNRIs and TCAs were estimated to increase the probability of
the transition while AAs were estimated to reduce the probability. For transitions from
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normal cognition directly to dementia, SSRIs, SNRIs and AAs were estimated to increase
the probability of the transition, but TCAs are associated with a significantly reduced
probability. For transitions from MCI to dementia, SSRIs, AAs and TCAs are associated
with increased probability for transition, but SNRIs is associated with a reduced
probability for transition. The estimate for SSRI is significant. Finally, for transitions
from MCI back to normal cognition, all types of antidepressant are associated with
reduced odds, indicating that antidepressant use may prevent recovering from MCI to
normal. Figure 4.3 displays the adjusted odds ratios and the corresponding 95%
confidence intervals for transitions of interest for each class of antidepressant.
Markov cohort simulation analysis was conducted to evaluate the transition time
from one particular state to another. Times spent on transitions from normal cognition to
dementia and transitions from MCI to dementia for each class of antidepressant were of
the primary interest. Times were estimated by assuming different baseline ages and
different baseline depression status (Figure 4.4). In general, it takes longer time for
transitions from normal cognition to dementia compared to transitions from MCI to
dementia, regardless of the antidepressant use, baseline age or baseline depression status.
For transitions from normal cognition to dementia, different antidepressant users
would spend different lengths of time in the normal state before moving to dementia.
Participants in control group need the longest time to make the transition, while SNRI
users need the shortest time to make the transition, assuming fixed baseline ages and
depression status. SSRI users, AA users and TCA users need similar times for the
transition. Baseline age and baseline depression status will further influence the times for
transition. Increased baseline age would reduce the time spent in the normal state
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assuming fixed treatment and fixed baseline depression status. Participants with
depression at baseline will result in shorter transition times compared to participants
without depression at baseline assuming fixed treatment and fixed baseline age.
For transitions from MCI to dementia, participants in comparison group would
spend the longest time in the MCI state before moving to dementia while all the other
antidepressant users will move to dementia quicker than the controls assuming fixed
baseline age and baseline depression status. The differences in transition times among
different antidepressant classes are not obvious for transitions from MCI state as they are
for transitions from normal state. Increased baseline age would reduce the time spent in
the normal state assuming fixed treatment and fixed baseline depression status.
Participants with depression at baseline would have reduced transition times compared to
participants without depression at baseline assuming fixed treatment and fixed baseline
age.

4.4. Discussion
In this project, a multi-state Markov chain was implemented to evaluate the
effects of antidepressants on the risk of dementia while accounting for the time-varying
treatment and time-varying confounders. First, a series of three multinomial logistic
regression models were built to model log-odds of the one-step transitions between any
two transient states or the one-step transitions between a transient state and an absorbing
state, conditioned on the prior (transient) state. Second, a Markov cohort simulation
analysis was conducted using the estimated transition probabilities based on the fitted
models for those one-step transitions.
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The estimated effects of different classes of antidepressant on the one-step
transition suggested that in general antidepressant use is associated with increased odds
of moving towards the next worse cognitive status, and antidepressant use is also
associated with reduced odds of moving back to the previous healthier cognitive status. In
other words, antidepressant use was estimated to be associated with harmful impacts on
cognition. The estimated transition times associated with each class of antidepressant
illustrates the results obtained from the models. Antidepressant users would move quicker
from either normal state or MCI state to demented state compared to the non-users.
As discussed in Chapter Two, there are several explanations for the potential
mechanisms of the effects of antidepressants on dementia. For example, an animal study
has found that SSRI treatment is associated with imbalance zinc levels, which may lead
to neurofibrillary tangles, which is a marker of Alzheimer’s disease and cognitive
impairment73. Additionally, SNRI may increase user’s blood pressure64,70,

and

hypertension is a risk factor for vascular dementia and Alzheimer’s dementia71. However,
the association between antidepressant use and dementia may still be due to reverse
causality78, where preclinical neurodegenerative disease causes depression, which causes
antidepressant initiation, which induces the association between antidepressant use and
dementia.
Age is known to be a strong risk factor for cognitive decline99. In this study, the
effects of antidepressants on transition times were impacted by different baseline ages. It
would take less time for older antidepressant users to move to dementia compared with
younger antidepressant users across all antidepressant classes. There have been studies
suggesting that aging is associated with important changes in pharmacokinetics100-102. For
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example, compared with the younger antidepressant users, concerns for the
antidepressant users among the elderly included the differences in disposition, altered
sensitivity to side effects, potential drug-drug interactions, decreased homeostatic reserve
and possibly decreased sensitivity to antidepressant efficiency102.
The effects of antidepressants on transition times would also be influenced by
different baseline depression status. Antidepressant users who reported depression at
baseline would move to dementia faster than antidepressant users who did not report
depression at baseline across all antidepressant classes. Studies have concluded that
depression is a risk factor for cognitive declines81,82,103,104. However, we cannot rule out
the possibility that depression is merely an early manifestation, rather than a predictor, of
Alzheimer’s disease82,105.
The cognitive status at the “from-state” may have impacted on the effects of
antidepressant on the risk of dementia. The effects of antidepressant on transition times
differ among different classes for participants in the normal state, but such differences
were minimized for participants in the MCI state, although a clear difference between
non-users and antidepressant users remained. We do note that the SSRI group, which was
associated with increased odds of transition from normal to MCI or dementia, and from
MCI to dementia, is associated with the shortest times to dementia from the normal state.
There are several advantages for this study. First, our analysis allows for timevarying treatment and time-varying confounders, hence we were able to address the
potential changes of treatment regimen or participants’ characteristics over time. Second,
a subsequent benefit of the incorporation of time-varying treatment and confounders is
that we were able to account for the time-varying hazards for developing dementia. Third,
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our study permits participants to transition among different cognitive stages before
developing dementia, which is usually true in practice.
There are some limitations for this study. First, all transitions are assumed to
occur on the visit date, and any transitions among the transient states between the visits
are ignored. Second, we cannot rule out the possibility of reverse causality, where
antidepressant use is actually induced by depression as a comorbidity of preclinical
neurodegeneration, rather than being a predictor of cognitive decline78. Third, we need to
be aware that sleep disorders were not adjusted in the models due to the fact that the
variables associated with sleep disorders were not properly measured for the purpose of
this study.

4.5. Conclusion
In this study, we assessed the association between each class of antidepressant
and the probability of dementia while accounting for the time-varying risks for dementia
and the potential transitions among different cognitive stages before finally developing
dementia. Multi-state Markov models based on multinomial logistic regression were
constructed to model log-odds of the one-step transitions between any two transient states
or the one-step transitions between a transient state and an absorbing state, conditioned
on the prior (transient) state. A Markov cohort simulation analysis was conducted to
evaluate the predicted time for transition from one particular state to another using the
estimated transition probabilities from the estimated log-odds of those one-step
transitions.
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We found that in general antidepressant use is associated with increased odds of
moving towards the next worse cognitive status, and antidepressant use is also associated
with reduced odds of moving back to the previous healthier cognitive status. In addition,
it took less time for older antidepressant users to move to dementia compared with
youngers antidepressant users across all antidepressant classes. Finally, antidepressant
users who reported depression at baseline would move to dementia faster than
antidepressant users who did not report depression at baseline across all antidepressant
classes.
There are several directions for future studies. First, more accurate measurement
on transition times should be implemented. Second, in studies with longer follow-up,
reverse causality can be tested by excluding incident cases within the first pre-determined
number of years of treatment. Finally, the potential confounding effects of sleep disorders
should be adjusted when the data is available.
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Table 4.1. Summary of Subject Characteristics at the Initial Visit (N=11,939)
Variable
All subjects
Age (year)
76.0 ± 7.2
Pain meds
4397 (36.8%)
Depression
1979 (16.6%)
GDS score1
1 (0, 2)
Any other psychiatric disorders
483 (4.1%)
CDR2
0 (0, 0.5)
Cognitive status
Normal
7625 (63.9%)
MCI3
3595 (30.1%)
Impaired but not MCI
719 (6.0%)
Number of assessments
4 (2, 7)
Days between assessments
378 (358, 427)
Note: Mean ± S.D. are reported for normally-distributed continuous variables. Median
(Q1, Q3) are reported for non-normally-distributed variables. Frequency (%) are
reported for categorical variables.
1
Geriatric Depression Scale score
2
Standard CDR sum of boxes
3
Mild Cognitive Impairment

65

Table 4.2. One-step Transition Matrix (N=11,939)
Prior

Normal
MCI
Normal
29000 (88.7)
1903 (5.8)
MCI1
1016 (9.1)
7134 (64.2)
Impaired2
619 (22.3)
572 (20.6)
1
Mild Cognitive Impairment
2
Impaired but not MCI

Current
Impaired
785 (2.4)
479 (4.3)
1348 (59.2)

66

Dementia
242 (0.7)
1941 (17.5)
133 (4.8)

Death
773 (2.4)
534 (4.8)
104 (3.7)

Table 4.3. Adjusted Odds Ratios for Transitions among States
new

Prior

5
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Normal
MCI
Normal
-1.25 (0.89, 1.75)
SSRI1
MCI
-0.64 (0.39, 1.05)
Impaired
0.83 (0.48, 1.45)
0.53 (0.28, 0.97)
Normal
-1.60 (0.87, 2.94)
SNRI2
MCI
-0.37 (0.11, 1.21)
Impaired
0.68 (0.15, 3.02)
0.49 (0.10, 2.35)
Normal
-0.71 (0.40, 1.28)
3
AA
MCI
-0.41 (0.15, 1.16)
Impaired
0.65 (0.13, 3.19)
2.06 (0.64, 6.66)
TCA4
Normal
-1.23 (0.59, 3.67)
MCI
-0.57 (0.14, 2.32)
Impaired
0.45 (0.02, 8.75)
0.41 (0.02, 7.51)
Note: transitions of interest are marked bold
1
Selective serotonin reuptake inhibitors
2
Serotonin and norepinephrine reuptake inhibitors
3
Atypical antidepressants
4
Tri-cyclic antidepressants
5
Mild Cognitive Impairment
6
Impaired but not MCI

Current
Impaired6
1.42 (0.94, 2.15)
0.69 (0.38, 1.26)
-0.24 (0.03, 2.28)
1.26 (0.51, 3.09)
-1.23 (0.63, 2.42)
1.39 (0.60, 3.21)
-1.46 (0.58, 3.67)
0.08 (0.05, 0.14)
--

Dementia
1.23 (0.57, 2.65)
1.70 (1.28, 2.26)
0.52 (0.22, 1.23)
1.97 (0.44, 8.79)
0.57 (0.27, 1.19)
0.45 (0.09, 2.25)
1.06 (0.33, 3.40)
1.18 (0.68, 2.04)
5.12 (1.26, 20.72)
0.16 (0.11, 0.24)
1.22 (0.51, 2.90)
2.69 (0.17, 43.28)

Death
1.27 (0.77, 2.11)
1.70 (1.08, 2.67)
0.88 (0.36, 2.12)
2.96 (1.25, 6.97)
0.87 (0.32, 2.37)
0.20 (0.06, 0.63)
1.45 (0.78, 2.70)
1.04 (0.52, 2.10)
4.28 (0.99, 18.58)
0.93 (0.29, 3.00)
0.91 (0.24, 3.42)
4.36 (0.59, 32.30)

Figure 4.1. Study Cohort Derivation Flowchart
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Figure 4.2. Diagram of Possible Transitions between States
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Figure 4.3. Adjusted Odds Ratios for Transitions among States of Interest
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Figure 4.4. Predicted Times for Transitions of Interest
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CHAPTER FIVE. CONCLUSION
5.1. Study Summary
Given the public health significances of dementia and antidepressant use among
the elderly, it is important to understand the relationship between antidepressant use and
dementia development in this special population. The purpose of this research is to
investigate the effects of different classes of antidepressant medications on the risk of
dementia using causal inference strategies using data obtained from the National
Alzheimer’s Coordinating Center (NACC) Uniform Data Set (UDS).
In Chapter Two, a new users design retrospective cohort study was conducted to
evaluate the causal effects of different classes of antidepressant on the risk of dementia
by performing a Marginal Structural Cox Proportional Hazard Regression Model with an
Inverse Probability Weighting estimator. Significant causal effects of SSRIs, SNRIs, AAs
and TCAs on the risk of dementia were observed at the 0.05 significance level. In general,
the estimates were not sensitive to confounding by indication of psychiatric disorders,
genetic risk due to ApoE ε4 status, or treatment regime changes in later visits.
In Chapter Three, the impacts of sleep apnea and rapid-eye-movement behavior
disorder (RBD) as unmeasured confounders were assessed. Unmeasured confounding is a
threat to the validity of causal inference methods. In evaluating the effects of antidepressants, it is important to consider how common comorbidities of depression may
affect both the exposure to anti-depressants and the onset of cognitive impairment. A bias
factor formula for two binary unmeasured confounders was derived in order to account
for these variables. Monte Carlo analysis was implemented to estimate the distribution of
the bias factor for each class of antidepressant. The effects of antidepressants on the risk
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of dementia adjusted for both measured and unmeasured confounders were estimated.
Sleep apnea and RBD attenuated the effect estimates toward the null for SSRI, SNRI and
AA on the risk of dementia. Sleep apnea and RBD may not be confounders between TCA
use and dementia risk.
In Chapter Four, a multi-state Markov chain with three transient states (normal
cognition, impaired but not MCI, and MCI) and two absorbing states (dementia and death
prior to dementia) was built to account for the treatment changes over time and timevarying covariates. A series of polytomous logistic regression models were constructed to
model the log-odds of transitions between any two transient states and transitions
between a transient state and an absorbing state. A Markov cohort simulation analysis
was conducted using the estimated transition probabilities from the estimated log-odds
from the model results. In general, antidepressant use was estimated to be associated with
harmful impacts on cognition. The estimated transition times for each class of
antidepressant confirms the results obtained from the models. Antidepressant users would
move quicker from either normal state or MCI state to demented state compared to the
controls.

5.2. Strengths and Limitations
A major strength of this research is that we were able to simulate a “pseudo
randomized study” with observational data following the intent-to-treatment principles,
thus the causal effects of different classes of antidepressant could be estimated.
Additionally, the potential uncontrolled confounding effects of sleep disorders were
adjusted to further improve the accuracy of the estimation. Hence, our research accounts
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for several limitations that previous studies in the way that the marginal effects of
antidepressant on the risk of dementia were estimated, rather than the conditional effects.
Another strength of this research is that the time-varying treatment and timevarying confounders were addressed by implementing a multi-state Markov chain, hence
we were able to address the potential changes of treatment regimen or participants’
characteristics over time. In other words, the time-varying hazards for developing
dementia were investigated in this research.
However, one subsequent limitation is that the multi-state Markov chain was only
able to estimate the conditional effects of antidepressants, thus we cannot conclude causal
relationship between any class of the antidepressant under investigation which potentially
changes over time and the risk of dementia. Moreover, to use multi-state Markov chain,
we need to assume that all transitions occurred on the visit date, and any transitions
among the transient states between the visits were ignored.
Another limitation of this research is that we could not rule out the possibility of
reverse causality, where antidepressant use is actually induced by depression as a
comorbidity of preclinical neurodegeneration, rather than being a predictor of cognitive
declines78. If the reverse causality is true, then the association we observed between
antidepressant use and dementia may not be used for causal inference.

5.3. Future Research
There are several directions for future research suggested by the studies in this
dissertation. First, we did not explore the possibility of causal inference in multi-state
Markov chain due to the limited timeframe, however, this can be a direction for future
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study. For example, the Inverse Probability Weighting or G-computation could be
incorporated into the models to estimate the marginal effects of the treatment of interest.
Second, the possibility of reverse causality should be checked. In this study, the followup time was not long enough to assess the possibility of reverse causality, however, for
studies with decades of follow-up, incident cases that arise in the first pre-determined
number of years of treatment can be excluded to test the reverse causality hypothesis79.
Finally, the medication measurement is not accurate in the UDS. In future studies, better
measurements are expected. For example, during the UDS visit, participants were only
asked if they were using any medication within two weeks before the current visit. Thus,
details about the doses or indications associated with the reported medications were not
available. Besides better measurements on the exposure, more accurate measurements on
the timings of cognitive transition are needed to better estimate the impacts of some
certain exposure on cognitive declines, and measurements on risk factors such as physical
activities and diet habits should be implemented.
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